NEJM:BNT162b2或ChAdOx1 nCoV-19疫苗对B.1.617(delta)变异株仍有效

2021-07-22 MedSci原创 MedSci原创

与新冠肺炎病毒alpha变异株相比,完成2次疫苗接种后,对Delta变异的预防效果仅下降了5%-7%,疫苗效果的大幅降低仅出现在只完成1次接种的人群中。这一结果再次证实了完成2次疫苗接种的必要性。

自2021年3月底以来,印度2019年冠状病毒病(covid-19)病例激增,其中B.1.617(delta)变异株占主导。B.1.617.2(delta)变异株于2020年12月在印度首次发现,截至2021年5月19日,已在6大洲的43个国家发现该变异株。近日研究人员考察了BNT162b2及ChAdOx1 nCoV-19疫苗对B.1.617(delta)变异株的免疫效果。

本次研究在英国开展,为病例对照研究,以评估BNT162b2及ChAdOx1 nCoV-19对B.1.617(delta)变异株引起的症状性疾病的预防效果。

在完成第一针疫苗接种后,无论是BNT162b2或ChAdOx1 nCoV-19疫苗,人群对Delta变异株的预防效果为30.7%,显著低于对Alpha变异株的预防效果(48.7%)。在完成2剂量疫苗接种人群中,疫苗表现出较好的Delta变异免疫效果:对于BNT162b2疫苗,在完成2次接种后,对Alpha变异株的预防效果为93.7%,而对Delta变异的预防效果为88.0%。对于ChAdOx1 nCoV-19疫苗,在完成2次接种后,对Alpha变异株的预防效果为74.5%,而对Delta变异的预防效果为67.0%。

研究认为,新冠肺炎病毒alpha变异株相比,完成2次疫苗接种后,对Delta变异的预防效果仅下降了5%-7%,疫苗效果的大幅降低仅出现在只完成1次接种的人群中。这一结果再次证实了完成2次疫苗接种的必要性。

原始出处:

Jamie Lopez Bernal et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med,July 21,2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
    2021-07-22 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
    2021-07-22 ms4000001441347419

    签到

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
    2021-07-22 ms5000000518166734

    已读已读已读已读学习学习学习学习,

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
    2021-07-22 竹山

    不错

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1782942, encodeId=23f91e829425a, content=<a href='/topic/show?id=b78845e0ba' target=_blank style='color:#2F92EE;'>#ChAdOx1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4570, encryptionId=b78845e0ba, topicName=ChAdOx1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Fri Oct 08 18:13:39 CST 2021, time=2021-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1342860, encodeId=982c134286091, content=<a href='/topic/show?id=34cb381023e' target=_blank style='color:#2F92EE;'>#变异#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38102, encryptionId=34cb381023e, topicName=变异)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=78c32500188, createdName=12498dabm77暂无昵称, createdTime=Sat Jul 24 08:13:39 CST 2021, time=2021-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035702, encodeId=7ef91035e02f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jul 22 20:13:39 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001761, encodeId=fbc41001e61d9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a2b85466921, createdName=ms4000001441347419, createdTime=Thu Jul 22 18:06:54 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001751, encodeId=72851001e51de, content=已读已读已读已读学习学习学习学习,, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f03a5433387, createdName=ms5000000518166734, createdTime=Thu Jul 22 17:49:25 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001747, encodeId=4c471001e4742, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:27:43 CST 2021, time=2021-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1001745, encodeId=270e1001e45e9, content=签到, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26865554750, createdName=竹山, createdTime=Thu Jul 22 17:21:39 CST 2021, time=2021-07-22, status=1, ipAttribution=)]
    2021-07-22 竹山

    签到

    0

相关资讯

Science:重磅,老药新用,只需6天减少99%新冠病毒载量,还可作为光谱抗病毒药

2021年7月20日,芝加哥大学等机构的研究人员在国际顶尖学术期刊 Science 发表了题为:Masitinib is a broad coronavirus 3CL inhibitor that

JAMA:世卫组织研究证实IL-6抑制剂可降低新冠肺炎住院患者死亡风险

新冠肺炎住院患者使用IL-6抑制剂治疗可降低28天死亡风险。

Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性

临床前数据显示,瑞丹维单抗(CT-P59)对德尔塔变异株(B.1.617.2,首先在印度发现)有强效中和活性;结果显示,采用治疗剂量CT-P59治疗的所有动物存活率为100%,动物体内病毒被根除

NEJM:bamlanivimab-etesevimab双中和抗体疗法治疗轻中度新冠肺炎

对于临床症状为轻中度,但进展风险较高的新冠肺炎患者,bamlanivimab-etesevimab双中和抗体治疗可显著降低患者新冠肺炎住院及死亡风险,大幅降低病毒载量

JAMA:卡那奴单抗可改善重症新冠肺炎住院患者预后

对于重症新冠肺炎患者,IL-1β抑制剂卡那奴单抗可显著提高患者29天内无需机械通气存活率

Blood:新冠肺炎或MIS-C儿童和青少年患者的血栓发生率

新冠肺炎或 MIS-C患儿的院内死亡率为2.3%(13/564),但发生了TE的患儿的死亡率激增至28%(5/18)